Novartis: positive data for malaria treatment

(CercleFinance.com) - Novartis and Medicines for Malaria Venture (MMV) announce positive efficacy and safety data for a new treatment for malaria-infected babies under 5 kg.


The positive data come from the Phase II/III CALINA study, demonstrating that a new formulation of Coartem (artemether-lumefantrine) developed for malaria-infected babies under 5 kg has the required pharmacokinetic profile and good efficacy and safety.

The trial was conducted in several African countries. The data, which will be presented this week at the 8th Pan-African Malaria Conference of the Multilateral Initiative on Malaria (MIM Society) in Kigali, have been submitted for regulatory review.

Management says that it is delighted with the positive results of our CALINA study and to be one step closer to introducing an effective malaria treatment for all age groups, including vulnerable newborns, committed to the fight against malaria for over two decades, and this successful trial represents another step towards ensuring that everyone has access to appropriate antimalarial treatment.

Novartis and MMV aim to make treatment available as soon as possible to the youngest infants, who currently lack access to evidence-based treatment options.


Copyright (c) 2024 CercleFinance.com. All rights reserved.